GET DAILY SIGNALSAmgen (AMGN) Q1 2026 Earnings Preview: Momentum Meets Challenges
Key Takeaways
- Analysts expect Q1 2026 revenue of approximately $8.5 billion, a roughly 5% increase from $8.1 billion in Q1 2025.
- Consensus adjusted earnings per share (EPS) forecast stands at $4.74, reflecting a potential decline from prior-year levels amid pricing pressures.
- Amgen reaffirmed full-year 2026 guidance for revenue between $37.0 billion and $38.4 billion, and adjusted EPS of $21.60 to $23.00.
- Key growth drivers include Repatha, Evenity, and Blincyto, with expected sales of $820 million, $567 million, and $410 million, respectively.
- Investors will scrutinize updates on the obesity drug pipeline, including MariTide, and biosimilar competition risks.
- Amgen has beaten EPS estimates in the past five quarters, heightening expectations for another positive surprise.
Why This Earnings Report Matters for Amgen Investors
Amgen's (AMGN) Q1 2026 earnings, set for release after market close on April 30, 2026, arrive at a critical juncture for this biotech leader. After a solid 2025 with 10% revenue growth to $36.8 billion, the company carries forward momentum from its broad lineup of blockbuster drugs. From what I see, investors are keenly watching if volume growth in high-margin products like Repatha for cholesterol and Tezspire for asthma can counter pricing headwinds and the threat of biosimilar erosion on older drugs. This report should offer initial clues on full-year guidance progress and pipeline developments, especially in the competitive obesity space, all of which could shape the stock's valuation in a volatile sector.
What to Expect from Q1 Results
Wall Street looks for Q1 revenue between $8.49 billion and $8.58 billion, marking about 5% growth from $8.1 billion a year ago, fueled by strong demand for newer therapies. The consensus adjusted EPS sits at $4.74, which may dip from recent quarters due to one-off items and margin squeezes, yet it remains well above GAAP levels.
Product highlights include projected sales of $820 million for Repatha, $567 million for Evenity, and $410 million for the oncology drug Blincyto. Amgen's full-year outlook holds steady at $37.0-$38.4 billion in revenue and $21.60-$23.00 adjusted EPS, suggesting consistent quarterly advances. The company has topped EPS estimates for the last five quarters, often leading to share strong performance after earnings. I also checked these trends using Tickeron’s AI Screener to gauge how AMGN stacks up against biotech peers. Key areas to monitor include gross margins and R&D investment in candidates like MariTide.
AI Screener: My Go-To Tool for Stock Analysis
In my research process, I rely on Tickeron’s AI Screener, an AI-driven tool that lets me sift through thousands of stocks and ETFs using filters for technical patterns, fundamentals, trends, volatility, and predictive signals. It streamlines finding trade ideas, breakout stocks, or sector opportunities far faster than manual scans. One thing that stands out is how it helps me compare AMGN to its industry on metrics like growth and volatility—definitely worth exploring to sharpen your own analysis.
Market Sentiment and Stock Positioning Ahead of Earnings
AMGN shares have eased about 6% in recent weeks, as caution builds around biosimilar threats and pricing in a high-rate backdrop. Overall sentiment leans positive, buoyed by the earnings beat streak and steady guidance, though it's mixed. Options imply volatility of 5-7%, hinting at possible post-earnings moves. Downside risks involve soft volume or guidance tweaks, but strong results on marquee products could trigger a bounce.
Looking Ahead: Guidance, Pipeline, and Risks to Track
After the report, I'll be listening closely to management's take on 2026 guidance. The outlook envisions mid-single-digit revenue growth, backed by 18 products eyeing over $1 billion in annual sales. Pipeline updates, particularly Phase 3 results for obesity hopeful MariTide, could point to major upside in a market set to top $100 billion.
Cost dynamics deserve scrutiny: gross margins hover above 75%, but R&D at roughly 20% of revenue might climb with advancing trials. Volume signals from U.S. and international markets, including Europe, will show if demand holds against payer resistance. Biosimilars hitting Enbrel and Neulasta present challenges, yet shifts into rare diseases and inflammation add balance. Watch for mid-year trial data and filings to gauge AMGN's path through 2026.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
AMGN in upward trend: 10-day moving average crossed above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 44 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 147 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.530) is normal, around the industry mean (-1.476). P/E Ratio (28.696) is within average values for comparable stocks, (21.871). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.038) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
Advertisement